SGLT-2i and Cardiovascular Outcomes: A Meta-Analysis of The Asian Cohort

Abstract

Sir, Recent diabetes guidelines have upgraded the position of sodium glucose cotransporter 2 inhibitors (SGLT-2i) based on the publication of cardiovascular outcomes trials (CVOT). However, divergent signals have emerged from the 3 CVOTs. It is speculated that these differences were due to differing patient population and cardiovascular (CV) risk status, suggesting that the benefits of SGLT-2i were driven primarily by their effect on the pump (hospitalization for heart failure (hHF) and CV death) and not on the pipe (myocardial infarction, stroke & peripheral arterial disease). [1]